LMB763: A selective FXR partial agonist
January’s molecule, a Novartis FXR partial agonist (LMB763 (nidufexor)), modulates the farnesoid X nuclear receptor (FXR), a hot target for NASH due to promising prior clinical activity with bile acid-derived FXR agonists such as OCA. OCA, however, showed significant rates of side effects including itching (likely due to GPBAR1 bile acid receptor agonism) and elevated LDL cholesterol levels, which is problematic for the more heart-disease-susceptible NASH patient population. [...]
January’s molecule, a Novartis FXR partial agonist (LMB763 (nidufexor)), modulates the farnesoid X nuclear receptor (FXR), a hot t...